Taxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patients

Alberto Farolfi, Corradina Della Luna, Angela Ragazzini, Elisa Carretta, Nicola Gentili, Carla Casadei, Michele Aquilina, Domenico Barone, Martina Minguzzi, Dino Amadori, Oriana Nanni, Giampaolo Gavelli

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background. The impact of cytotoxic agents on the risk of acute allergy-like adverse reactions (ARs) to intravenous iodinated contrast media (ICM) injections is unknown. Methods. We retrospectively reviewed 13,565 computed tomography (CT) scans performed in a consecutive cohort of cancer patients from January 1, 2010 to December 31, 2012. Episodes of acute ICM-related ARs were reported to the pharmacovigilance officer. The following matched comparisons were made: tax code, gender, primary tumor, antineoplastic therapy, and date of last cycle. Concomitant antineoplastic treatment was classified into five groups: platinum, taxane, platinum plus taxane, other, and no treatment group (no therapy had been administered in the previous 24 months). Logistic regression was used to estimate odds ratio (OR) and 95% confidence interval (CI) to evaluate the risk of acute ICM-related ARs. Results. Of 10,472 contrast-enhanced CT scans, 97 (0.93%; 95% CI: 0.74-1.11) ICM-related ARs were reported, 11 of which (0.1%) were severe, including one fatality. The overall incidence was significantly higher in patients aged

Original languageEnglish
Pages (from-to)823-828
Number of pages6
JournalThe oncologist
Volume19
Issue number8
DOIs
Publication statusPublished - 2014

Fingerprint

Taxoids
Contrast Media
Platinum
Antineoplastic Agents
Neoplasms
Tomography
Confidence Intervals
Pharmacovigilance
Taxes
Cytotoxins
Group Psychotherapy
Hypersensitivity
Therapeutics
Logistic Models
Odds Ratio
Injections
Incidence
taxane

Keywords

  • Cancer patients
  • Contrast-enhanced CT
  • Hypersensitivity
  • Iodinated contrast media
  • Risk of adverse event

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Taxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patients. / Farolfi, Alberto; Luna, Corradina Della; Ragazzini, Angela; Carretta, Elisa; Gentili, Nicola; Casadei, Carla; Aquilina, Michele; Barone, Domenico; Minguzzi, Martina; Amadori, Dino; Nanni, Oriana; Gavelli, Giampaolo.

In: The oncologist, Vol. 19, No. 8, 2014, p. 823-828.

Research output: Contribution to journalArticle

Farolfi, A, Luna, CD, Ragazzini, A, Carretta, E, Gentili, N, Casadei, C, Aquilina, M, Barone, D, Minguzzi, M, Amadori, D, Nanni, O & Gavelli, G 2014, 'Taxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patients', The oncologist, vol. 19, no. 8, pp. 823-828. https://doi.org/10.1634/theoncologist.2013-0470
Farolfi, Alberto ; Luna, Corradina Della ; Ragazzini, Angela ; Carretta, Elisa ; Gentili, Nicola ; Casadei, Carla ; Aquilina, Michele ; Barone, Domenico ; Minguzzi, Martina ; Amadori, Dino ; Nanni, Oriana ; Gavelli, Giampaolo. / Taxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patients. In: The oncologist. 2014 ; Vol. 19, No. 8. pp. 823-828.
@article{80b51eab6911428ca0d873f0b1d6e15c,
title = "Taxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patients",
abstract = "Background. The impact of cytotoxic agents on the risk of acute allergy-like adverse reactions (ARs) to intravenous iodinated contrast media (ICM) injections is unknown. Methods. We retrospectively reviewed 13,565 computed tomography (CT) scans performed in a consecutive cohort of cancer patients from January 1, 2010 to December 31, 2012. Episodes of acute ICM-related ARs were reported to the pharmacovigilance officer. The following matched comparisons were made: tax code, gender, primary tumor, antineoplastic therapy, and date of last cycle. Concomitant antineoplastic treatment was classified into five groups: platinum, taxane, platinum plus taxane, other, and no treatment group (no therapy had been administered in the previous 24 months). Logistic regression was used to estimate odds ratio (OR) and 95{\%} confidence interval (CI) to evaluate the risk of acute ICM-related ARs. Results. Of 10,472 contrast-enhanced CT scans, 97 (0.93{\%}; 95{\%} CI: 0.74-1.11) ICM-related ARs were reported, 11 of which (0.1{\%}) were severe, including one fatality. The overall incidence was significantly higher in patients aged",
keywords = "Cancer patients, Contrast-enhanced CT, Hypersensitivity, Iodinated contrast media, Risk of adverse event",
author = "Alberto Farolfi and Luna, {Corradina Della} and Angela Ragazzini and Elisa Carretta and Nicola Gentili and Carla Casadei and Michele Aquilina and Domenico Barone and Martina Minguzzi and Dino Amadori and Oriana Nanni and Giampaolo Gavelli",
year = "2014",
doi = "10.1634/theoncologist.2013-0470",
language = "English",
volume = "19",
pages = "823--828",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",
number = "8",

}

TY - JOUR

T1 - Taxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patients

AU - Farolfi, Alberto

AU - Luna, Corradina Della

AU - Ragazzini, Angela

AU - Carretta, Elisa

AU - Gentili, Nicola

AU - Casadei, Carla

AU - Aquilina, Michele

AU - Barone, Domenico

AU - Minguzzi, Martina

AU - Amadori, Dino

AU - Nanni, Oriana

AU - Gavelli, Giampaolo

PY - 2014

Y1 - 2014

N2 - Background. The impact of cytotoxic agents on the risk of acute allergy-like adverse reactions (ARs) to intravenous iodinated contrast media (ICM) injections is unknown. Methods. We retrospectively reviewed 13,565 computed tomography (CT) scans performed in a consecutive cohort of cancer patients from January 1, 2010 to December 31, 2012. Episodes of acute ICM-related ARs were reported to the pharmacovigilance officer. The following matched comparisons were made: tax code, gender, primary tumor, antineoplastic therapy, and date of last cycle. Concomitant antineoplastic treatment was classified into five groups: platinum, taxane, platinum plus taxane, other, and no treatment group (no therapy had been administered in the previous 24 months). Logistic regression was used to estimate odds ratio (OR) and 95% confidence interval (CI) to evaluate the risk of acute ICM-related ARs. Results. Of 10,472 contrast-enhanced CT scans, 97 (0.93%; 95% CI: 0.74-1.11) ICM-related ARs were reported, 11 of which (0.1%) were severe, including one fatality. The overall incidence was significantly higher in patients aged

AB - Background. The impact of cytotoxic agents on the risk of acute allergy-like adverse reactions (ARs) to intravenous iodinated contrast media (ICM) injections is unknown. Methods. We retrospectively reviewed 13,565 computed tomography (CT) scans performed in a consecutive cohort of cancer patients from January 1, 2010 to December 31, 2012. Episodes of acute ICM-related ARs were reported to the pharmacovigilance officer. The following matched comparisons were made: tax code, gender, primary tumor, antineoplastic therapy, and date of last cycle. Concomitant antineoplastic treatment was classified into five groups: platinum, taxane, platinum plus taxane, other, and no treatment group (no therapy had been administered in the previous 24 months). Logistic regression was used to estimate odds ratio (OR) and 95% confidence interval (CI) to evaluate the risk of acute ICM-related ARs. Results. Of 10,472 contrast-enhanced CT scans, 97 (0.93%; 95% CI: 0.74-1.11) ICM-related ARs were reported, 11 of which (0.1%) were severe, including one fatality. The overall incidence was significantly higher in patients aged

KW - Cancer patients

KW - Contrast-enhanced CT

KW - Hypersensitivity

KW - Iodinated contrast media

KW - Risk of adverse event

UR - http://www.scopus.com/inward/record.url?scp=84905453253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905453253&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2013-0470

DO - 10.1634/theoncologist.2013-0470

M3 - Article

C2 - 25063226

AN - SCOPUS:84905453253

VL - 19

SP - 823

EP - 828

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 8

ER -